Atlas Trials

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Clinical trial NCT03262545 · UNKNOWN

Trial details

NCT number
NCT03262545
Sponsor
Sichuan Cancer Hospital and Research Institute
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Angiogenesis Inhibitors,Ovarian Neoplasms
Start date
2017-08-27
Primary completion
2020-08-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.